EUVIMEDEUVIMED entdecken
Crossref

Both carvedilol and cimetidine alleviate cisplatin-induced nephrotoxicity via downregulating OCT2

Huan Wu, Yichun Ning, Zhaoxing Sun, Ji Ji, Min Lu, Xiaoyan Jiao, Xiaoliang Xu, Xiaoqiang Ding, Xin Cheng, Xiaofang Yu

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2025-06 · 1871 (5) · 167754

DOI: 10.1016/j.bbadis.2025.167754 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2025-06. Verfasst von Huan Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, …. Hauptthemen laut MEDLINE: Cimetidine, Cisplatin, Organic Cation Transporter 2, Acute Kidney Injury. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Science and Technology Innovation Plan Of Shanghai Science and Technology Commission, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cisplatin is a common chemotherapy agent for solid tumors but severe nephrotoxicity limits its application, with no effective pharmacological treatments. Organic cation transporter 2 (OCT2) is involved in cisplatin uptake in kidneys. This study aimed to find drugs with promising clinical applications that could prevent cisplatin-induced acute kidney injury (Cis-AKI) by inhibiting OCT2. METHODS: The mRNA level of OCT2 was examined in human induced pluripotent stem cells (iPSCs) from Cis-AKI patients and paired non-AKI patients. The association between OCT2 and Cis-AKI was investigated by HEK293FT cells and kidney organoids. We screened potential compounds exhibiting protective effects against Cis-AKI in US Food and Drug Administration-approved drugs through virtual screening and activity screening. Subsequently, we determined the effects of these compounds on OCT2 expression, cisplatin uptake, and apoptosis in cells, kidney organoids and mice. A549 and HeLa cells were adopted to observe the influence of drugs on the anti-tumor function of cisplatin. RESULTS: Compared to non-AKI patients, the OCT2 mRNA levels of iPSCs from Cis-AKI patients were elevated. OCT2 exhibits similar expression patterns in kidney organoids and human kidney tissues. Furthermore, the overexpression of OCT2 in kidney organoids and HEK293FT cells exacerbated the injury caused by cisplatin. Carvedilol and cimetidine were identified as potent OCT2 inhibitors by drug screening. Further analysis revealed that the pretreatment of carvedilol or cimetidine downregulated OCT2, reduced cisplatin uptake, and alleviated cisplatin-induced apoptosis, but the combination of the two drugs didn't further improve these outcomes. Additionally, carvedilol and cimetidine didn't compromise the cisplatin-induced cell death in A549 and HeLa cells. CONCLUSION: Our study confirmed that carvedilol and cimetidine exert protective effects against Cis-AKI by inhibiting OCT2, without altering the anti-tumor effects of cisplatin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CimetidineCisplatinOrganic Cation Transporter 2Acute Kidney InjuryCarvedilolHumansAnimalsMiceHEK293 CellsDown-RegulationHeLa CellsA549 CellsApoptosisMaleAntineoplastic AgentsInduced Pluripotent Stem CellsKidney

Stichwörter der Autor:innen

CarvedilolCimetidineCisplatin-induced acute kidney injury (Cis-AKI)Drug screeningKidney organoidsThe organic cation transporter 2 (OCT2)

Substanzen

CimetidineCisplatinOrganic Cation Transporter 2CarvedilolSLC22A2 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China.
  • Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China; Shanghai Medical Center for Kidney, Shanghai, China; Shanghai I…
  • State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, Ch…

Förderung

  • Science and Technology Innovation Plan Of Shanghai Science and Technology Commission
  • National Natural Science Foundation of China

Zitieren

APA

Wu, H., Ning, Y., Sun, Z., Ji, J., Lu, M., Jiao, X., Xu, X., Ding, X., Cheng, X., & Yu, X. (2025). Both carvedilol and cimetidine alleviate cisplatin-induced nephrotoxicity via downregulating OCT2. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1871(5), 167754. https://doi.org/10.1016/j.bbadis.2025.167754

Vancouver

Wu H, Ning Y, Sun Z, Ji J, Lu M, Jiao X, et al. Both carvedilol and cimetidine alleviate cisplatin-induced nephrotoxicity via downregulating OCT2. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2025;1871(5):167754. doi:10.1016/j.bbadis.2025.167754

BibTeX
@article{Wu2025,
  author = {Wu, Huan and Ning, Yichun and Sun, Zhaoxing and Ji, Ji and Lu, Min and Jiao, Xiaoyan and Xu, Xiaoliang and Ding, Xiaoqiang and Cheng, Xin and Yu, Xiaofang},
  title = {Both carvedilol and cimetidine alleviate cisplatin-induced nephrotoxicity via downregulating OCT2},
  journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease},
  year = {2025},
  volume = {1871},
  number = {5},
  pages = {167754},
  doi = {10.1016/j.bbadis.2025.167754}
}
Kostenlos starten →